Manila Healthtek Inc.

Manila Healthtek Inc. is a Philippines-based biotechnology firm focused on developing and commercializing innovative diagnostic solutions that enhance public health and agricultural sustainability. Manila Healthtek Inc. specializes in crafting advanced diagnostic kits, founded in 2013 in the Philippines.

The company has secured PHP 70 million in funding from the National Development Company in August 2024, marking its most recent deal. The firm has accomplished one total deal since inception. Manila Healthtek does not have known subsidiaries or parent companies, and there are no notable pivots in its business strategy. The founder's history is currently unavailable, and specific global office locations are not disclosed.

Manila Healthtek Inc. specializes in the development and commercialization of innovative diagnostic kits aimed at improving public health outcomes. Their flagship products include the FDA-approved Biotek-M™ Dengue Aqua Kit, which facilitates early detection of dengue fever, and an ASF (African Swine Fever) detection kit designed to support the swine industry in the Philippines. These products are developed using advanced molecular biology techniques and aim to provide accessible and cost-effective solutions for infectious disease diagnostics.

The company serves a diverse client base, including hospitals, laboratories, and agricultural stakeholders, primarily within the Philippines but also extending to other regions where infectious diseases pose significant health challenges. By leveraging local expertise and technology, Manila Healthtek Inc. addresses critical health issues, contributing to both public health and local agricultural sustainability. Manila Healthtek Inc.

generates revenue through direct sales of its diagnostic products to healthcare institutions and agricultural businesses. Transactions typically occur through structured agreements with hospitals and clinics, where the company supplies its proprietary diagnostic kits, such as the Biotek-M™ series and the ASF detection kit. These engagements may be complemented by collaborative partnerships with academic and research institutions, enhancing the reach and impact of their innovations. The pricing structure for these products is aligned with market standards for medical diagnostics, reflecting the value of their unique, locally developed solutions.

By positioning itself as a leader in biotechnology within the diagnostics sector, Manila Healthtek Inc. capitalizes on the growing demand for efficient and reliable diagnostic tools in both healthcare and agricultural markets. In August 2024, Manila Healthtek Inc. raised PHP 70 million from new investor National Development Company.

The company will utilize this funding to complete its molecular diagnostic and medical device manufacturing facility in Marikina City. Future plans include the launch of additional diagnostic products aimed at enhancing public health and expanding into new markets within Southeast Asia by 2025.